{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"15"}],"title":"Died"},{"measurements":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"58"}],"title":"Censored (includes participants still in survival follow up and terminated prior to death)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months","title":"Overall Survival (Count)","type":"SECONDARY","unitOfMeasure":"Participants"}